Increased pressure stimulates aberrant dendritic cell maturation

• Autorzy: Craig D H , Schaubert K.L. , Shiratsuchi H. , Kan-Mitchell J. , Basson M.D.
• Języki publikacji: EN

Abstrakty

EN

Patients with malignancy typically exhibit abnormal dendritic cell profiles. Interstitial tumor pressure is increased 20-50mmHg over that in normal tissue. We hypothesized that elevated pressure in the tumor microenvironment may influence dendritic cell (DC) phenotype and function. Monocyte-derived immature and mature DC isolated from healthy human donors were exposed to either ambient or 40 mmHg increased pressure at 37°C for 12 hours, then assessed for expression of CD80, CD86, CD83, CD40, MHC-I and MHC-II. IL-12 production and phagocytosis of CFSE-labeled tumor lysate were assessed in parallel. Elevated pressure significantly increased expression of all co-stimulatory and MHC molecules on mature DC. Immature DC significantly increased expression of CD80, CD86, CD83 and MHC-II, but not MHC-I and CD40, versus ambient pressure controls. Pressure-treated immature DC phenotypically resembled mature DC controls, but produced low IL-12. Phenotypic maturation correlated with decreased phagocytic capacity. These results suggest increased extracellular pressure may cause aberrant DC maturation and impair tumor immunosurveillance.

Słowa kluczowe

EN

dendritic cell; pressure; maturation; cancer; interstitial tumour pressure; normal tissue; maintenance; surveillance

• Wydawca: -
• Czasopismo: Cellular and Molecular Biology Letters
• Rocznik: 2008
• Tom: 13
• Numer: 2
• Opis fizyczny: p.260-270,fig.,ref.

Twórcy

autor

Craig D H

• John D. Dingell VA Medical Center and Wayne State University, 4646 John R. Street, Detroit, MI 48201, USA

autor

Schaubert K.L.

autor

Shiratsuchi H.

autor

Kan-Mitchell J.

autor

Basson M.D.

Bibliografia

• 1. de Visser, K.E., Eichten, A. and Coussens, L.M. Paradoxical roles of the immune system during cancer development. Nat. Rev. Cancer 6 (2006) 24-37.
• 2. Gabrilovich, D. Mechanisms and functional significance of tumour-induced dendritic-cell defects. Nat. Rev. Immunol. 4 (2004) 941-952.
• 3. Banchereau, J. and Steinman, R.M. Dendritic cells and the control of immunity. Nature 392 (1998) 245-252.
• 4. Satthaporn, S., Robins, A., Vassanasiri, W., El-Sheemy, M., Jibril, J.A., Clark, D., Valerio, D. and Eremin, O. Dendritic cells are dysfunctional in patients with operable breast cancer. Cancer Immunol. Immunother. 53 (2004) 510-518.
• 5. Garrity, T., Pandit, R., Wright, M.A., Benefield, J., Keni, S. and Young, M.R. Increased presence of CD34+ cells in the peripheral blood of head and neck cancer patients and their differentiation into dendritic cells. Int. J. Cancer 73 (1997) 663-669.
• 6. Schwaab, T., Schned, A.R., Heaney, J.A., Cole, B.F., Atzpodien, J., Wittke, F. and Ernstoff, M.S. In vivo description of dendritic cells in human renal cell carcinoma. J. Urol. 162 (1999) 567-573.
• 7. Avigan, D. Dendritic cells: development, function and potential use for cancer immunotherapy. Blood Rev. 13 (1999) 51-64.
• 8. Steinman, R.M. The dendritic cell system and its role in immunogenicity. Annu. Rev. Immunol. 9 (1991) 271-296.
• 9. Schott, M. Immunesurveillance by dendritic cells: potential implication for immunotherapy of endocrine cancers. Endocr. Relat. Cancer 13 (2006) 779-795.
• 10. Mihalyo, M.A., Hagymasi, A.T., Slaiby, A.M., Nevius, E.E. and Adler, A.J. Dendritic cells program non-immunogenic prostate-specific T cell responses beginning at early stages of prostate tumorigenesis. Prostate (2007) 67 536- 546.
• 11. Li, H.S., Verginis, P. and Carayanniotis, G. Maturation of dendritic cells by necrotic thyrocytes facilitates induction of experimental autoimmune thyroiditis. Clin. Exp. Immunol. 144 (2006) 467-474.
• 12. Rutella, S., Danese, S. and Leone, G. Tolerogenic dendritic cells: cytokine modulation comes of age. Blood 108 (2006) 1435-1440.
• 13. Boucher, Y. and Jain, R.K. Microvascular pressure is the principal driving force for interstitial hypertension in solid tumors: implications for vascular collapse. Cancer Res. 52 (1992) 5110-5114.
• 14. Gutmann, R., Leunig, M., Feyh, J., Goetz, A.E., Messmer, K., Kastenbauer, E. and Jain, R.K. Interstitial hypertension in head and neck tumors in patients: correlation with tumor size. Cancer Res. 52 (1992) 1993-1995.
• 15. Less, J.R., Posner, M.C., Boucher, Y., Borochovitz, D., Wolmark, N. and Jain, R.K. Interstitial hypertension in human breast and colorectal tumors. Cancer Res. 52 (1992) 6371-6374.
• 16. Nathan, S.S., DiResta, G.R., Casas-Ganem, J.E., Hoang, B.H., Sowers, R., Yang, R., Huvos, A.G., Gorlick, R. and Healey, J.H. Elevated physiologic tumor pressure promotes proliferation and chemosensitivity in human osteosarcoma. Clin. Cancer Res. 11 (2005) 2389-2397.
• 17. Shiratsuchi, H. and Basson, M.D. Extracellular pressure stimulates macrophage phagocytosis by inhibiting a pathway involving FAK and ERK. Am. J. Physiol. Cell Physiol. 286 (2004) C1358-1366.
• 18. Hellman, P. and Eriksson, H. Early activation markers of human peripheral dendritic cells. Hum. Immunol. 68 (2007) 324-333.
• 19. O'Doherty, U., Peng, M., Gezelter, S., Swiggard, W.J., Betjes, M., Bhardwaj, N. and Steinman, R.M. Human blood contains two subsets of dendritic cells, one immunologically mature and the other immature. Immunology 82 (1994) 487-493.
• 20. Basson, M.D., Yu, C.F., Herden-Kirchoff, O., Ellermeier, M., Sanders, M.A., Merrell, R.C. and Sumpio, B.E. Effects of increased ambient pressure on colon cancer cell adhesion. J. Cell Biochem. 78 (2000) 47-61.
• 21. Walsh, M.F., Woo, R.K., Gomez, R. and Basson, M.D. Extracellular pressure stimulates colon cancer cell proliferation via a mechanism requiring PKC and tyrosine kinase signals. Cell Prolif. 37 (2004) 427-441.
• 22. Blander, J.M. Signalling and phagocytosis in the orchestration of host defence. Cell Microbiol. 9 (2007) 290-299.
• 23. Reis e Sousa, C., Stahl, P.D. and Austyn, J.M. Phagocytosis of antigens by Langerhans cells in vitro. J. Exp. Med. 178 (1993) 509-519.
• 24. Tsujitani, S., Kakeji, Y., Watanabe, A., Kohnoe, S., Maehara, Y. and Sugimachi, K. Infiltration of dendritic cells in relation to tumor invasion and lymph node metastasis in human gastric cancer. Cancer 66 (1990) 2012- 2016.
• 25. Scarpino, S., Stoppacciaro, A., Ballerini, F., Marchesi, M., Prat, M., Stella, M.C., Sozzani, S., Allavena, P., Mantovani, A. and Ruco, L.P. Papillary carcinoma of the thyroid: hepatocyte growth factor (HGF) stimulates tumor cells to release chemokines active in recruiting dendritic cells. Am. J. Pathol. 156 (2000) 831-837.
• 26. Lespagnard, L., Gancberg, D., Rouas, G., Leclercq, G., de Saint-Aubain Somerhausen, N., Di Leo, A., Piccart, M., Verhest, A. and Larsimont, D. Tumor-infiltrating dendritic cells in adenocarcinomas of the breast: a study of 143 neoplasms with a correlation to usual prognostic factors and to clinical outcome. Int. J. Cancer 84 (1999) 309-314.
• 27. Tong, A.W. and Stone, M.J. Prospects for CD40-directed experimental therapy of human cancer. Cancer Gene Ther. 10 (2003) 1-13.
• 28. Pirtskhalaishvili, G., Shurin, G.V., Esche, C., Cai, Q., Salup, R.R., Bykovskaia, S.N., Lotze, M.T. and Shurin, M.R. Cytokine-mediated protection of human dendritic cells from prostate cancer-induced apoptosis is regulated by the Bcl-2 family of proteins. Br. J. Cancer 83 (2000) 506-513.
• 29. Cella, M., Scheidegger, D., Palmer-Lehmann, K., Lane, P., Lanzavecchia, A. and Alber, G. Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T-T help via APC activation. J. Exp. Med. 184 (1996) 747-752.
• 30. Saito, Y., Yanagawa, Y., Kikuchi, K., Iijima, N., Iwabuchi, K. and Onoe, K. Low-dose lipopolysaccharide modifies the production of IL-12 by dendritic cells in response to various cytokines. J. Clin. Exp. Hematop. 46 (2006) 31-36.
• 31. Karni, A., Abraham, M., Monsonego, A., Cai, G., Freeman, G.J., Hafler, D., Khoury, S.J. and Weiner, H.L. Innate immunity in multiple sclerosis: myeloid dendritic cells in secondary progressive multiple sclerosis are activated and drive a proinflammatory immune response. J. Immunol. 177 (2006) 4196-4202.
• 32. Schmidt, C., Giese, T., Ludwig, B., Mueller-Molaian, I., Marth, T., Zeuzem, S., Meuer, S.C. and Stallmach, A. Expression of interleukin-12-related cytokine transcripts in inflammatory bowel disease: elevated interleukin23p19 and interleukin-27p28 in Crohn's disease but not in ulcerative colitis. Inflamm. Bowel Dis. 11 (2005) 16-23.
• 33. Saito, H., Tsujitani, S., Ikeguchi, M., Maeta, M. and Kaibara, N. Relationship between the expression of vascular endothelial growth factor and the density of dendritic cells in gastric adenocarcinoma tissue. Br. J. Cancer 78 (1998) 1573-1577.
• 34. Della Bella, S., Gennaro, M., Vaccari, M., Ferraris, C., Nicola, S., Riva, A., Clerici, M., Greco, M. and Villa, M.L. Altered maturation of peripheral blood dendritic cells in patients with breast cancer. Br. J. Cancer 89 (2003) 1463-1472.
• 35. Menetrier-Caux, C., Montmain, G., Dieu, M.C., Bain, C., Favrot, M.C., Caux, C. and Blay, J.Y. Inhibition of the differentiation of dendritic cells from CD34(+) progenitors by tumor cells: role of interleukin-6 and macrophage colony-stimulating factor. Blood 92 (1998) 4778-4791.
• 36. Ratta, M., Fagnoni, F., Curti, A., Vescovini, R., Sansoni, P., Oliviero, B., Fogli, M., Ferri, E., Della Cuna, G.R., Tura, S., Baccarani, M. and Lemoli, R.M. Dendritic cells are functionally defective in multiple myeloma: the role of interleukin-6. Blood 100 (2002) 230-237.